TruScreen, DaltonBio collaborate on HPV product expansion

TruScreen has announced a collaboration with Hangzhou Dalton Bioscience to expand its human papillomavirus (HPV) product offerings.

The non-binding memorandum of understanding (MOU) provides a framework for the distribution and marketing of complementary HPV-related in-vitro diagnostics (IVD) products through TruScreen's global distribution network, under the TruScreen brand.

TruScreen said the collaboration aims to enhance access to innovative cervical cancer screening and detection solutions.

The company said it will conduct due diligence on DaltonBio's HPV-related IVD products in the short term and, if successful, it will seek to become a global distributor of DaltonBio's HPV-related IVD products, excluding the US and Canada.

DaltonBio will also explore opportunities to assist TruScreen's AI-enabled real-time cervical screening device within its distribution network, particularly in China and South America.